Sentences with phrase «cancer tumor samples»

Researchers searched through all thyroid cancer tumor samples in the hospital's possession from the study period for patients who lived in at - risk regions Dauphin, York, eastern Cumberland, Lancaster and western Lebanon counties.

She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens / targets in breast cancer tumor samples.

Not exact matches

The diagnosis of cancer and study of disease progression is often accomplished by examining a tumor sample containing many billions or even trillions of cells.

This study analyzed preserved tumor samples from 43 prostate cancer patients who later received radiation therapy after rising PSA levels were detected following a radical prostatectomy.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

Now researchers have taken a small step in that direction: They've deciphered a genetic «signature» that, in several tumor samples, appears to predict whether a cancer will spread.

31: The percentage of genetic mutations shared by all the tumor samples taken from a patient with kidney cancer.

To that end, in collaboration with the University of Zurich and MD Anderson Cancer Center, the researchers tested melanoma tumor samples from human patients undergoing treatment with the same targeted therapies.

The investigators looked at 4,278 tumor samples from a tissue repository of patients with GI tract cancers.

The finding, reported by a Stand Up to Cancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking thCancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking thCancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking thcancer that no longer responded to standard hormone - blocking therapy.

Spearheaded by first author Christopher McNair, PhD, a graduate student in the laboratory of Dr. Knudsen, the study undertook an extensive analysis of tumor samples and cell - free DNA samples from patients with advanced, lethal - stage prostate cancer.

Using tumor samples from a patient, they do lab tests to determine which substances can first make the different types of cancer cells uniform and then effectively kill them.

A global analysis of metabolites and small molecules in urine samples from patients with adrenal cancer has identified four biochemicals that, when measured together, can distinguish malignant from benign adrenal tumors, according to study results presented at the 2015 Annual Clinical Congress of the American College of Surgeons.

The latter, presented by Eric Lander of the Broad Institute in Cambridge, Massachusetts, would systematically sequence tumor samples for mutations involved in cancer to speed up the search for new drugs and diagnostics.

From tissue and cell samples from five glioblastoma patients, the scientists obtained 33 individual cancer cells capable of reproduction, which grew into very different tumors in the lab.

A total of 67 biochemical features discriminated cancer from benign tumors in these samples, but only four specific metabolites could be considered as biomarkers for cancer: creatinine riboside, tryptophan, Nε, Nε, Nε - trimethyllysine, and 3 - methylhistidine.

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

Nana - Sinkam and his colleagues examined lung - tumor samples from 81 patients with stage - 1 nonsmall - cell lung cancer and tumor - cell lines.

To better understand the formation of metastases in pancreatic cancer, Christine Iacobuzio - Donahue, M.D., Ph.D., professor of pathology at Memorial Sloan Kettering Cancer Center, collected tumor samples from eight patients with the most common form of pancreatic cancer (pancreatic ductal adenocarcinoma) immediately after their dcancer, Christine Iacobuzio - Donahue, M.D., Ph.D., professor of pathology at Memorial Sloan Kettering Cancer Center, collected tumor samples from eight patients with the most common form of pancreatic cancer (pancreatic ductal adenocarcinoma) immediately after their dCancer Center, collected tumor samples from eight patients with the most common form of pancreatic cancer (pancreatic ductal adenocarcinoma) immediately after their dcancer (pancreatic ductal adenocarcinoma) immediately after their deaths.

A multicenter team of researchers reports that a full genomic analysis of tumor samples from a small number of people who died of pancreatic cancer suggests that chemical changes to DNA that do not affect the DNA sequence itself yet control how it operates confer survival advantages on subsets of pancreatic cancer cells.

«Shifting protein networks in breast cancer may alter gene function: Changes in gene function in tumor samples correlate with patient survival.»

By growing organoids from tumor samples, researchers can create minitumors and use them to study how cancer develops or to test drugs.

The team chose to compare breast tissue from healthy individuals with tumor samples taken from breast cancer patients — including both primary tumors that had not spread from the breast to other body sites, and highly aggressive, metastatic tumors.

Unlike other solid tumors, there has been limited progress in understanding the contribution of genetic risk factors to the development of uveal melanoma, researchers say, primarily due to the absence of comprehensive genetic data from patients as the large sample cohorts for this rare cancer type have not been available for research.

The team is now working to create a repository of pancreatic tumor samples, coordinating with the National Cancer Institute.

For example, cancer cells floated above denser blood cells, which could allow clinicians to spot rare circulating tumor cells in a patient sample.

Using all the existing data that was available, Andrechek, along with MSU doctoral student Daniel Hollern, analyzed 1,172 mouse mammary tumor samples from 26 different preclinical models and was able to compile one of the largest databases to show which strains of mice were best suited to study a particular type of human breast cancer.

Analyzing the poly - G profiles of primary and metastatic colon cancer samples from 22 patients revealed that how the primary and metastatic tumors related to each other was different for each patient.

Answering important clinical questions — such as whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.

The researchers were able to replicate this finding by comparing the healthy thyroid tissues in GTEx to 500 samples taken from thyroid tumors, compiled by The Cancer Genome Atlas, and giving support to the extensive impact of FOXE1 on cellular state.

«We discovered chimeric RNAs in the tumor samples — made when DNA deletions create unnatural products that can drive cancer,» says Nicolas Robine, co-first author and NYGC Computational Biologist.

«Furthermore, analysis of tumor samples from large cohorts of colorectal cancer patients revealed that activation of the loop is associated with metastasis,» Hermeking reports.

Working in mouse models of breast cancer and breast tumor samples from patients, Longmore and his colleagues showed that a protein that sits on the surface of tumor cells, called DDR2, binds to collagen and activates a multistep pathway that encourages tumor cells to spread.

An additional set of 18 prostate cancer tissue samples was analyzed by qPCR and five lncRNAs were found to be significantly higher in prostate tumor tissues compared with matched normal tissues.

«Our findings show that high - intensity circulating tumor DNA sequencing is possible and may provide invaluable information for clinical decision - making, potentially without any need for tumor tissue samples,» said lead study author Pedram Razavi, MD, PhD, a medical oncologist and instructor in medicine at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY.

Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research Institute (NCRI) Cancer Conference in LiveCancer Conference in Liverpool.

The researchers studied 24 tumor samples from breast cancer patients after the samples were transplanted into mice.

Overall, including all genomic variations present in most if not all tumor cells (clonal) as well as those present only in subsets of the cancer cells (subclonal) from tumor tissue, the researchers detected a total of 864 genetic changes in tissue samples across the three tumor types, and 627 (73 %) of those were also found in the blood.

In a landmark paper, Cancer Research UK funded scientists alongside an international team of researchers read all of the DNA in tumor samples from 10 men with prostate cCancer Research UK funded scientists alongside an international team of researchers read all of the DNA in tumor samples from 10 men with prostate cancercancer.

To explore this idea, Hopkins oncologists Dung Le, Luis Diaz, and others looked for mismatch repair mutations in tumor samples from patients with advanced colon cancer and other cancer types whose tumors had stopped responding to other treatments.

As a next step, Guha, Avadhani and colleagues plan to extend this study to in vivo mouse models and will also investigate these mechanisms in tumor samples from human breast cancer patients.

Fifteen teams analyzed nearly 500 patients» tumors for genetic aberrations and sequenced the protein - coding DNA of 316 samples — by far the largest cancer sequencing effort to date.

More than 150 cancer researchers have divvied up the work of sequencing about 500 tumor samples for each of some 20 cancer types (10,000 samples in total) at a cost of more than $ 375 million.

Seven tumors, he says, is not a large enough sample to see the entire spectrum of mutations in prostate cancer.

The idea is to sequence 10,000 tumor samples for each of several common cancers, such as breast and prostate.

Notably, the researchers found that, using their methods, highly reactive TILs could be obtained from some 90 % of the ovarian cancer patients whose tumor samples they examined.

In this study, samples were taken from patients» tumors during surgery and transplanted into mice to grow new pancreatic cancer tumors.

Charles Swanton, a cancer geneticist at the Francis Crick Institute in London, and colleagues analyzed 1,206 clear - cell renal cell carcinoma (ccRCC) tumor samples from 101 patients as part of the Tracking Cancer Evolution through therapy (TRACERx) prcancer geneticist at the Francis Crick Institute in London, and colleagues analyzed 1,206 clear - cell renal cell carcinoma (ccRCC) tumor samples from 101 patients as part of the Tracking Cancer Evolution through therapy (TRACERx) prCancer Evolution through therapy (TRACERx) program.

To further validate our result in clinical samples, we obtained primary tumor from patients with advanced breast cancer and the tissue was passaged once in nonobese diabetic / severe combined immunodeficient mouse without in vitro culture.

Thus, in a panel of breast cancer samples, we identified tumor cells that did not form part of the bulk tumor mass, but instead were interspersed within the adjacent stroma — as if forming the forefront of cancer cell invasion.